Illumina (ILMN) confirms shareholders voted to elect eight of nine Illumina director nominees
Get Alerts ILMN Hot Sheet
Join SI Premium – FREE
Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that based on the preliminary results of its 2023 Annual Meeting, Illumina shareholders have voted to elect eight of nine Illumina director nominees – Francis deSouza,
Illumina issued the following statement:
"Illumina thanks shareholders for their continued support of the company, which remains committed to its mission of improving human health by unlocking the power of the genome. We appreciate the constructive shareholder feedback throughout this process and are committed to delivering on our plan to accelerate shareholder value creation. We will continue to provide transparent and effective communication as we move forward together.
We would like to welcome
We also thank
The company also noted that shareholders approved the proposal to ratify auditors, one-year frequency on say-on-pay, and the stock incentive plan proposal; and shareholders did not approve the company's say-on-pay proposal.
The results announced today are considered preliminary and are subject to certification by the independent Inspector of Elections. The final certified results are expected to be provided in a Current Report filed on Form 8-K with the U.S. Securities and Exchange Commission within the next four business days.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shake Shack (SHAK) Announces Resignation of Jonathan Sokoloff from Board, Cuts Board Size to 10 from 11
- Las Vegas Sands (LVS) stock slips despite earnings, revenue beat in Q1
- Vista Outdoor (VSTO) CSG Sends Letter to Senator J.D. Vance Addressing His Concerns Regarding Planned Acquisition of Vista Outdoor’s Sporting Products Business (VSTO)
Create E-mail Alert Related Categories
Board Changes, Corporate News, Hedge FundsRelated Entities
Carl IcahnSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!